![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Aeterna Zentaris to Distribute Armune’s Apifiny Test in the U.S.
Aeterna Zentaris to Distribute Armune’s Apifiny Test in the U.S.
![correct_handshake.gif](https://www.fdanews.com/ext/resources/test/Device_Images/handshake.gif?t=1576815772&width=430)
Aeterna Zentaris has secured a co-marketing agreement with Kalamazoo, Mich.-based Armune BioScience to distribute Apifiny, a non-PSA blood test for the detection of prostate cancer.
Under the agreement, Aeterna Zentaris will distribute the test in U.S. territories and receive a commission for each test performed resulting from the promotion. Additional financial terms were not disclosed.
Armune’s Apifiny is based on the measurement of eight prostate cancer-specific autoantibodies in human serum, which are produced and amplified by the immune system in the presence of prostate cancer cells. — Michael Cipriano
Upcoming Events
-
21Oct